The next era of pharmaceutical innovation: from emerging technologies to scalable solutions

Artificial intelligence, advanced therapies, sustainable formulation and next-generation drug delivery are creating new opportunities across the pharmaceutical industry. However, turning innovation into practical, scalable and commercially viable solutions remains a significant challenge.

How can pharmaceutical companies move beyond AI pilots to deliver meaningful impact? What will it take to scale advanced therapies and bring more sophisticated medicines to patients? And how are digital technologies changing the partnerships that underpin drug development and manufacturing?

Bringing together perspectives from industry leaders, pharmaceutical specialists and academic experts, this report explores seven important developments shaping the future of pharma - examining both the opportunities ahead and the challenges that will determine their impact.

Inside the report:

• AI in clinical trials: Why data access, governance and accountability remain barriers to adoption
• Advanced therapies: The challenge of scaling CAR-T manufacturing and improving patient access
• Next-generation drug delivery: How nanotechnology, 3D printing and AI count enable more sophisticated medicines
• Smarter pharmaceutical partnerships: How AI is changing expectations of CDMOs and collaboration across the value chain
• Sustainable pharma and formulation innovation: The role of collaboration, excipients and data-driven expertise.

Industry perspectives:

Research and insight from Informa Markets, with contributions from experts associated with Fresenius Group, Pfizer CentreOne, Lubrizol, Thermo Fisher Scientific, 20/15 Visioneers and Sandip Institute of Pharmaceutical Sciences.